Manon H.J. Hillegers, M.D., Ph.D., of Utrecht University, is looking for biomarkers for bipolar disorder in adolescence, which is peak time for bipolar onset. The project will apply magnetic resonance imaging studies to compare the brains of un-medicated adolescents at high genetic risk with healthy controls to observe how vulnerability for bipolar disorder affects brain function.
Beny Lafer, M.D., Ph.D., of the University of Sao Paulo, proposes to conduct a trial of creatine monohydrate, a medication that boosts energy metabolism, as a treatment strategy for bipolar depression, based on the hypothesis that creatine improves depressive symptoms through changes in the brain levels of metabolites of energy production. Via a technology called phosphorus magnetic resonance spectroscopy, the trial will examine relevant brain events before and after creatine treatment.
Christopher G. Beevers, Ph.D., of the University of Texas at Austin, wants to determine the role of genetic variation in how individuals respond to treatment for depression. Single nucleotide polymorphisms, or SNPs (pronounced "snips"), are variations in the DNA sequence of a gene. Dr. Beevers will apply a newly developed technique, genome-wide complex trait analysis, to assess 500,000 SNPs associated with rare and common genetic variations as predictors of treatment response.
Dost ngr, M.D., Ph.D., of Harvard University, is investigatin
|Contact: Sally Corbett|
Brain & Behavior Research Foundation